Decoding Prostate Cancer: Can Sex Hormones Predict Treatment Success?
"New research unveils the potential of serum sex steroids as key indicators in predicting the effectiveness of androgen deprivation therapy for recurrent prostate cancer, offering hope for more personalized treatment strategies."
Prostate cancer remains a significant health challenge for men worldwide. As therapeutic options expand, identifying biomarkers to predict treatment response becomes increasingly vital. Recent research focuses on the potential of serum sex steroids to serve as prognostic indicators in patients undergoing androgen deprivation therapy (ADT) for recurrent prostate cancer. This approach could revolutionize how we personalize cancer treatments.
Androgen deprivation therapy (ADT) is a cornerstone treatment for prostate cancer, but its effectiveness can vary. Doctors need better ways to determine which patients will respond well to ADT and which might require alternative strategies early on. Previous studies have shown testosterone levels can predict time to castration resistance, but understanding the roles of other sex steroids could offer even greater insights.
This article delves into a post-hoc analysis of the PR.7 trial, exploring the potential of serum sex steroids as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. The research assesses the predictive power of these hormones in relation to castration resistance, prostate cancer survival, and overall survival, offering a new perspective on personalized prostate cancer management.
ADT Use and Changing Recommendations
Androgen deprivation therapy (ADT) has increasingly been used in earlier stages of prostate cancer, even though mature data from large randomized trials cited in a review suggested no survival advantage from earlier intervention. Until 2018, National Comprehensive Cancer Network guidelines recommended ADT with radiation for all men with intermediate-risk disease; after intermediate risk was divided into favorable and unfavorable categories, that recommendation was limited to unfavorable intermediate-risk disease. A 2024 patient-organisation-initiated online survey examined ADT’s effects on health-related quality of life and communication, areas its authors said were underexplored. In England, a study examined national prescribing trends for injectable GnRH agonists from 2015 to 2024.
ADT as Standard Treatment
ADT is a first-line treatment for locally advanced tumors and recurrent or metastatic prostate cancer, and its widespread use means clinicians should be familiar with its common side effects. Intermittent ADT uses scheduled treatment and off-treatment periods; a 2020 review discusses its protocols and the available safety evidence. For metastatic castration-sensitive disease, 2025 guideline reporting describes combination therapy with ADT and androgen-receptor pathway inhibitors and/or chemotherapy as the standard of care. Risk stratification using criteria from trials such as STAMPEDE and LATITUDE helps guide treatment intensity.
More Than Eight Decades of ADT
ADT has been a main management strategy for prostate cancer for more than eight decades. A 2022 review describes luteinizing hormone-releasing hormone agonists as a common modern means of delivering androgen deprivation. The treatment’s rationale rests on the importance of androgen signaling in prostate cancer development and progression; hormonal manipulation has consequently been a mainstay for metastatic disease.
Harnessing Hormones: How Sex Steroids Impact Prostate Cancer Treatment
The study retrospectively analyzed data from Canadian patients in the PR.7 trial who received continuous ADT following biochemical recurrence post-radiotherapy. Researchers measured various sex steroid levels using mass spectrometry and correlated these levels with clinical outcomes such as time to castration-resistant prostate cancer (CRPC), prostate cancer survival, and overall survival.
- Estrone (E1) and Estradiol (E2): Higher levels were significantly associated with a shorter time to CRPC, suggesting these estrogens may promote resistance to ADT.
- DHEA and AST: Increases in serum DHEA and AST levels over time were also linked to a shorter time to CRPC, indicating a potential adaptive response within the tumor microenvironment.
- Testosterone, DHT, and AD: Higher levels correlated with castration resistance
Hormones as Potential Response and Prognostic Markers
A study of metastatic castration-resistant prostate cancer included patients whose serum hormone tests were obtained within two weeks before abiraterone acetate treatment, examining serum prolactin as a potential predictor of response. In localized prostate cancer, preoperative circulating 11-oxygenated androgen levels were associated with metastasis-free survival after radical prostatectomy, and levels were affected by 5α-reductase inhibitor treatment. Laboratory findings also report that 4-OHE2 increased cell viability under bicalutamide treatment and promoted prostate cancer stem-cell characteristics; an IL6-neutralizing antibody reversed these effects. Separately, a systematic review and meta-analysis published in 2024 examined ADT’s relationship with neurocognitive disorders.
Comparing ADT Schedules and Delivery Options
In a randomized study, patients whose PSA fell to 4 ng/mL or lower were assigned to continuous or intermittent androgen deprivation. A 2023 meta-analysis focused on updating comparisons of prostate-cancer-specific and non-prostate-cancer mortality to help inform selection between these ADT approaches. For advanced prostate cancer, newer delivery options described alongside traditional LHRH agonist depot injections include transdermal oestradiol patches and oral LHRH antagonists. Hormone therapies reduce hormones such as testosterone to slow tumor growth, whereas nonhormone treatments such as chemotherapy and radiation act through other approaches.
The Future of Prostate Cancer Treatment: Personalized Approaches Based on Hormonal Signatures
This research underscores the importance of considering a broader range of sex hormones when managing prostate cancer patients undergoing ADT. By monitoring these hormonal signatures, clinicians may be able to identify patients at higher risk of developing castration resistance and adjust treatment strategies accordingly.
Balancing Disease Control and Quality of Life
For specific clinical indications, ADT can induce prostate cancer regression, relieve symptoms, and prolong survival. It also has a well-described range of side effects that can harm quality of life, potentially requiring additional interventions or changes in the prostate cancer treatment plan. A 2024 systematic review and network meta-analysis set out to compare the effectiveness and safety of current combination therapies based on ADT. Expert commentary also highlights optimal use of ADT, evolving treatment practices, and recent clinical-trial data.
Questions Shaping Prostate Cancer Care in 2026
A 2026 outlook identifies three prominent treatment questions: how long to use ADT for localized high-risk disease, when and for whom PARP inhibitors belong in the hormone-sensitive metastatic setting, and whether an emerging T-cell engager platform may become the first immunotherapy to show genuine activity. These are presented as areas defining the treatment landscape in 2026. The outlook frames them as open questions rather than established clinical answers.
Treatment Burden and Cardiovascular Concerns
A review of cardiovascular health reports that ADT and androgen-receptor pathway inhibitors improve outcomes in advanced prostate cancer but increase cardiovascular toxicity, making cardiovascular disease a major competing source of morbidity and mortality. ADT is also associated with a significant treatment burden, including short-term effects and medical complications. A review describes ADT as standard treatment for advanced disease, where prostate cancer progression is driven by sustained androgen-receptor signaling.
Further research is needed to fully understand the mechanisms by which these sex steroids influence prostate cancer progression and resistance. However, these findings pave the way for developing more personalized and effective treatment approaches for prostate cancer patients.
The ability to predict treatment response based on sex steroid levels could significantly improve patient outcomes, reduce unnecessary treatments, and ultimately enhance the quality of life for men battling prostate cancer.